Pharmacogenetics of Warfarin Induction and Inhibition
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This research study will help determine how a person's genetic makeup affects their response
to drugs, the ability of the body to break down drugs, and their potential to experience an
interaction between drugs. The investigators are investigating the drug interactions with the
commonly used anticoagulant drug called warfarin. Warfarin is used for the treatment and
prevention of life-threatening abnormal blood clots such as deep vein thrombosis, heart
attacks, and strokes. The investigators chose warfarin for this study because it is a
commonly used drug and must be monitored closely to avoid side effects. The investigators are
interested in studying whether individuals with certain genetic profiles react differently to
warfarin when it is combined with other drugs. This research is being done to see if certain
genetic profiles require us to adjust warfarin doses differently than is needed for the
general population. Genetic profiles of subjects are determined from their participation in
the Pharmacogenetics Registry study (investigator Richard Brundage, University of Minnesota).
The study hypothesis is: Functionally defective CYP2C9 alleles attenuate the
warfarin-fluconazole inhibitory interaction and exacerbate the warfarin-rifampin inductive
interaction.
Phase:
N/A
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborator:
National Institute of General Medical Sciences (NIGMS)